What Is the Treatment of Non-occlusive Mesenteric Ischemia?
Non-occlusive mesenteric ischemia (NOMI) is a critical reduction in intestinal blood flow in the absence of mechanical arterial occlusion. First-line management requires simultaneous treatment of the precipitating cause alongside urgent measures to restore splanchnic perfusion.
Clinical Target
The primary measurable goal is normalization of serum lactate, which reflects restoration of adequate oxygen delivery to the intestinal mucosa.
Treatment Overview
The central principle is addressing the underlying precipitating cause in parallel with immediate resuscitative and haemodynamic measures. The protocol further incorporates anticoagulation and targeted intra-arterial intervention directed at mesenteric vasospasm.
Agent selection, sequencing, and the full decision algorithm are available in the structured protocol below.
References
DOI: 10.1186/s13017-022-00443-x
- The central principle of NOMI management is the treatment of the underlying precipitating cause.
- Fluid resuscitation, optimization of cardiac output, and elimination of vasopressors remain important primary measures.
- When the diagnosis of AMI is made, fluid resuscitation should commence immediately to enhance visceral perfusion. Electrolyte abnormalities should be corrected, and nasogastric decompression initiated.
- Additional treatment may include systemic anticoagulation (heparin) and the use of catheter-directed infusion of vasodilatory and antispasmodic agents, most commonly papaverine hydrochloride.
- The goals of therapy should address physiologic levels of oxygen delivery with continued monitoring of lactate level as an indication of perfusion improvement.
View source ↗